261 related articles for article (PubMed ID: 29978156)
21. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus.
Chauhan S; Manov A; Dhillon GS; Shah P
Cureus; 2023 Jan; 15(1):e33892. PubMed ID: 36819400
[TBL] [Abstract][Full Text] [Related]
22. Late-Onset Euglycemic Diabetic Ketoacidosis in a Patient With Massive Stroke Requiring Decompressive Craniectomy: A Case Report.
Hussaini SA; Aziz A; Musa M; Alamin M; Danjuma M
Cureus; 2021 Oct; 13(10):e18629. PubMed ID: 34765377
[TBL] [Abstract][Full Text] [Related]
23. Canagliflozin use in Type I diabetes mellitus.
Guthrie R
Postgrad Med; 2017 Apr; 129(3):336-339. PubMed ID: 27918226
[TBL] [Abstract][Full Text] [Related]
24. Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.
Gelaye A; Haidar A; Kassab C; Kazmi S; Sinha P
Case Rep Crit Care; 2016; 2016():1656182. PubMed ID: 27088018
[TBL] [Abstract][Full Text] [Related]
25. Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy.
Pace DJ; Dukleska K; Phillips S; Gleason V; Yeo CJ
J Pancreat Cancer; 2018; 4(1):95-99. PubMed ID: 30631862
[No Abstract] [Full Text] [Related]
26. Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report.
Matli VVK; Fariduddin MM; Asafo-Agyei KO; Bansal N
Clin Case Rep; 2021 Dec; 9(12):e05144. PubMed ID: 34917366
[TBL] [Abstract][Full Text] [Related]
27. Postoperative Euglycemic Ketoacidosis in Type 2 Diabetes Associated with Sodium-Glucose Cotransporter 2 Inhibitor: Insights Into Pathogenesis and Management Strategy.
Chandrakumar HP; Chillumuntala S; Singh G; McFarlane SI
Cureus; 2021 Jun; 13(6):e15533. PubMed ID: 34123681
[TBL] [Abstract][Full Text] [Related]
28. Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
Adachi J; Inaba Y; Maki C
Intern Med; 2017; 56(2):187-190. PubMed ID: 28090050
[TBL] [Abstract][Full Text] [Related]
29. [Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes].
Novik A V; García B C; Oliva I D
Rev Med Chil; 2017 Mar; 145(3):393-396. PubMed ID: 28548198
[TBL] [Abstract][Full Text] [Related]
30. When Guidelines Fail: Euglycemic Diabetic Ketoacidosis After Bariatric Surgery in a Patient Taking a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report.
Lane S; Paskar D; Hamed S; Goffi A
A A Pract; 2018 Jul; 11(2):46-48. PubMed ID: 29634546
[TBL] [Abstract][Full Text] [Related]
31. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol.
Rendell MS
Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593
[TBL] [Abstract][Full Text] [Related]
32. Euglycemic Diabetic Ketoacidosis: A Review.
Modi A; Agrawal A; Morgan F
Curr Diabetes Rev; 2017; 13(3):315-321. PubMed ID: 27097605
[TBL] [Abstract][Full Text] [Related]
33. The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.
Candelario N; Wykretowicz J
Oxf Med Case Reports; 2016 Jul; 2016(7):144-6. PubMed ID: 27471597
[TBL] [Abstract][Full Text] [Related]
34. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Peters AL; Buschur EO; Buse JB; Cohan P; Diner JC; Hirsch IB
Diabetes Care; 2015 Sep; 38(9):1687-93. PubMed ID: 26078479
[TBL] [Abstract][Full Text] [Related]
35. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
[TBL] [Abstract][Full Text] [Related]
36. Retrospective comparison of early- versus late-insulin therapy regarding effect on time to resolution of diabetic ketosis and ketoacidosis in dogs and cats: 60 cases (2003-2013).
DiFazio J; Fletcher DJ
J Vet Emerg Crit Care (San Antonio); 2016; 26(1):108-15. PubMed ID: 26551019
[TBL] [Abstract][Full Text] [Related]
37. Challenges in the Diagnosis of Euglycemic Diabetic Ketoacidosis in a Patient With Multiple Sclerosis Taking a Sodium-Glucose Cotransporter 2 Inhibitor.
Allison R; Goldstein D; Musso MW
J Emerg Med; 2019 Jul; 57(1):e1-e3. PubMed ID: 31027990
[TBL] [Abstract][Full Text] [Related]
38. Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor.
Pathak BD; Dhakal B; Bhattarai AM; Regmi BU; Mandal SK; Panta PR; Khadka S; Simkhada N
Ann Med Surg (Lond); 2022 Jul; 79():104118. PubMed ID: 35860094
[TBL] [Abstract][Full Text] [Related]
39. Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia.
Gammons DT; Counselman FL
Clin Pract Cases Emerg Med; 2018 Feb; 2(1):47-50. PubMed ID: 29849291
[TBL] [Abstract][Full Text] [Related]
40. Metabolic Acidosis in Postsurgical Patient on Canagliflozin and Metformin: A Case Report.
Darwish AM
A A Pract; 2019 Apr; 12(7):221-222. PubMed ID: 30234515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
